Numerous therapeutic agents have been demonstrated to initiate antitumor immune responses, thereby driving significant progress in cancer immunotherapy. However, clinical translation is severely limited by persistent challenges, including systemic toxicity, the immunosuppressive tumor microenvironment (TME), and low na...
Guan-Ran Wang, Kun Du, Di-Kai Sun et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.